The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ:IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19.
生物製藥行業很好地抵禦了 COVID-19 疫情， 股票納斯達克生物技術ETF （納斯達克：IBB）表現優於標準普爾500指數。這一防禦性部門還受益於導致 COVID-19 的 SARS-CoV-2 病毒。
It, therefore, comes as a no surprise that two of the top five gainers among biotech stocks are vaccine developers.
因此，生物科技股中漲幅最高的五大股中，有兩個是疫苗開發商也就不足爲奇了。
Here are the biotechs that advanced in excess of 1,000% thus far this year:
以下是今年迄今爲止增長超過1,000％的生物技術公司：
Novavax, Inc. (NASDAQ:NVAX) (Gain: +2799%)
Novavax, Inc. （納斯達克：NVAX)（收益：+2799%）
Much of Novavax's rally is attributable to its coronavirus vaccine program. The company identified its investigational vaccine, codenamed NVX-CoV2373, in early April. It is a stable, prefusion protein made using the company's proprietary nanoparticle technology, with Matrix-M adjuvant added to it.
Novavax的漲勢在很大程度上歸因於其冠狀病毒疫苗計劃。該公司在4月初發現了代號爲NVX-Cov2373的在研疫苗。它是一種穩定的預灌蛋白，使用該公司專有的納米顆粒技術製成，其中添加了Matrix-M佐劑。
Ahead of the initiation of the coronavirus vaccine program, the shares received a lift from positive developments concerning its influenza vaccine candidate NanoFlu.
在冠狀病毒疫苗計劃啓動之前，該股因其流感候選疫苗NanoFlu的積極進展而獲得提振。
After proceeding seamlessly with its vaccine program, Novavax Is currently facing a setback as it is experiencing a delay in the start of the U.S. leg of the late-stage study of NVX-CoV2373.
在順利進行疫苗計劃之後，Novavax目前正面臨挫折，因爲它正在經歷一場挫折 延遲 在NVX-CoV2373的後期研究的美國站開始時。
With two companies having already received conditional approvals for their vaccine candidates, Novavax is under pressure to expeditiously bring its coronavirus vaccine program to fruition.
由於兩家公司的候選疫苗已經獲得有條件批准，Novavax面臨着迅速實現其冠狀病毒疫苗計劃的壓力。
Vaxart Inc (NASDAQ:VXRT) (+1940%)
Vaxart Inc （納斯達克：VXRT) (+1940%)
This South San Francisco, California-based company was among the earliest to embark on a vaccine program against SARS-CoV-2.
這家總部位於加利福尼亞州南舊金山的公司是最早啓動針對SARS-CoV-2的疫苗計劃的公司之一。
The company announced in late January the initiation of the program based on its proprietary oral vaccine platform, VAAST. The company selected a lead candidate, an oral recombinant vaccine, in late May.
該公司在1月下旬宣佈基於其專有的口服疫苗平台VAAST啓動該計劃。該公司在5月下旬選擇了主要候選藥物，即口服重組疫苗。
In a bid to expedite its vaccine program, Vaxart appointed Andrei Floroiu, a biopharma industry veteran with experience in vaccine manufacturing, as its CEO in mid-June. The company filed an investigational new drug application for commencing the Phase 1 study in early August, and the application was cleared by the FDA in mid-September. About a month later, the company commenced the Phase 1 study of the investigational vaccine, codenamed VXA-CoV2-1.
爲了加快其疫苗計劃，Vaxart於6月中旬任命具有疫苗生產經驗的生物製藥行業資深人士安德烈·弗洛羅伊烏爲其首席執行官。該公司於8月初提交了啓動1期研究的在研新藥申請，該申請於9月中旬獲得美國食品藥品管理局的批准。大約一個月後，該公司開始了代號爲Vxa-CoV2-1的在研疫苗的1期研究。
"We look for interim follow-up safety updates at one month and two months post-dosing to be positive catalysts in 1Q21," HC Wainwright analyst Vernon Bernardino said in a note.
HC Wainwright分析師弗農·貝納迪諾在一份報告中表示：“我們希望給藥後一個月零兩個月的中期後續安全更新作爲21年第一季度的積極催化劑。”
Cardiff Oncology Inc (NASDAQ:CRDF) (+1,563%)
加的夫腫瘤學公司 （納斯達克：CRDF) (+1,563%)
Cardiff's shares had been flatlining since late-2018 up until the middle of 2020.
自2018年底到2020年中期，加的夫的股價一直持平。
The company's lead clinical-stage candidate, onvansertib is a third-generation, oral and highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine polo-like-kinase 1, which is over-expressed in multiple cancers including leukemias, lymphomas and solid tumors. It is being evaluated in multiple Phase 2 studies for indications, including metastatic castration-resistant prostate cancer, colorectal cancer and acute myeloid leukemia.
作爲該公司臨床階段的領先候選藥物，onvansertib是絲氨酸/蘇氨酸polo-like-激酶1的第三代口服高選擇性三磷酸腺苷競爭抑制劑，該激酶在包括白血病、淋巴瘤和實體瘤在內的多種癌症中過度表達。多項2期研究正在對其進行適應症評估，包括轉移性耐去勢前列腺癌、結直腸癌和急性髓系白血病。
The shares began turning the corner after the company reported a $13.5 million equity investment in mid-June. It got another leg-up in mid-September following a presentation at the ESMO virtual conference, providing data on onvansertib in KRAS-mutant metastatic colorectal cancer. The rally has accelerated since then.
該公司在6月中旬公佈了1,350萬美元的股權投資後，該股開始轉危爲安。在 9 月中旬又上漲了演示文稿 在ESMO虛擬會議上，提供了有關onvansertib在Kras突變轉移性結直腸癌中的數據。從那時起，漲勢加速了。
Genprex Inc (NASDAQ:GNPX) (+1,297%)
Genprex Inc （納斯達克：GNPX) (+1,297%)
This gene therapy company received a shot in the arm from a mid-February licensing agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes. The stock, however, gave back much of the gain in about a month.
這家基因療法公司在2月中旬與匹茲堡大學簽訂的許可協議中受到了打擊，該協議涉及一種可能治癒1型和2型糖尿病的糖尿病基因療法。但是，該股在大約一個月內回吐了大部分漲幅。
The company's immunogene therapy Reqorsa is being evaluated for non-small cell lung cancer.
該公司的免疫基因療法Reqorsa正在接受非小細胞肺癌評估。
Trillium Therapeutics Inc (NASDAQ:TRIL) (+1,068%)
延齡草藥業公司 （納斯達克：審判) (+1,068%)
The clinical stage immuno-oncology company has been broadly higher this year, although its shares have pulled back since early December.
儘管自12月初以來股價已回落，但這家處於臨床階段的免疫腫瘤學公司今年大幅上漲。
The company is developing two pipeline assets: TTI-621 and TTI-622. TTI-621 is currently being evaluated in a phase 1 trial in patients with relapsed/refractory hematologic malignancies, while TTI-622 is being studied in a two-part, phase 1a/1b study in patients with advanced relapsed or refractory lymphoma or multiple myeloma.
該公司正在開發兩項管道資產：TTI-621 和 TTI-622。TTI-621 目前正在一項針對復發/難治性血液系統惡性腫瘤患者的 1 期試驗中進行評估，而一項針對晚期復發或難治性淋巴瘤或多發性骨髓瘤患者的分爲兩部分的 1a/1b 期研究正在對 TTI-622 進行研究。
Photo by Owen Beard on Unsplash.